Global Goserelin Drug Market

Goserelin Drug Comprehensive Study by Indication (Prostate Cancer, Breast Cancer, Endometriosis, Gynaecological Disorders), Sales Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy), Dose (3.6mg, 10.8 mg) Players and Region - Global Market Outlook to 2030

Goserelin Drug Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Goserelin Drug
Goserelin is a synthetic analogue of a naturally occurring gonadotropin-releasing hormone (GnRH). Zoladex contains the drug goserelin, which belongs to a class of medications called gonadotropin-releasing hormone (GnRH) agonists. Zoladex is a type of hormone therapy that works to lower levels of sex hormones such as testosterone and estrogen. Goserelin is a gonadotrophin-releasing hormone (GnRH) analogue which, during continuous administration, down-regulates the pituitary-ovarian gonadal axis and reduces levels of the gonadotropins, luteinising hormone and follicle-stimulating hormone.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


Competition among existing players is due to the Goserelin Drug market share occupied by leading players. The industry leader is engaged in offering innovative and superior quality products to cater to the ever-growing demand for Goserelin Drug Market. The companies are implementing strategic activities such as acquisitions and mergers along with collaboration with companies in other industries to aid them in improving sustenance and maintaining their competitive advantage. Analyst at AMA Research estimates that china and United States Players will contribute the maximum growth to Global Goserelin Drug market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Bachem AG (Switzerland), Aspen Holdings (South Africa), TerSera Therapeutics USA (United States), BCN Peptides S.A (Spain), Alvogen (United States), Shenzhen JYMed Technology Co., Ltd, (JYMed) (China), Neurocrine Biosciences, Inc. (United States), Hemmo Pharmaceuticals Pvt Ltd. (India) and ALP Pharm Beijing Co., Ltd. (China) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Goserelin Drug market by and Region.



On the basis of geography, the market of Goserelin Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Indication, the sub-segment i.e. Prostate Cancer will boost the Goserelin Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Sales Channel, the sub-segment i.e. Retail Pharmacy will boost the Goserelin Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Dose, the sub-segment i.e. 3.6mg will boost the Goserelin Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Government support to reduce cancer proliferation

Market Growth Drivers:
Effective alternate treatment for surgery or estrogen therapy in prostate cancer and Growing prevalence of ovarian and prostate cancer

Challenges:
Availability of alternative drugs such as leuprorelin, triptorelin.

Restraints:
Side Effects associated with Goserelin Drug

Opportunities:
Ongoing clinical trials using Goserelin drug for cancer treatment

Market Leaders and their expansionary development strategies
In September 2018, Luye Pharma announced that its independently developed drug, Goserelin Acetate Extended-release Microspheres for Injection (LY01005), has entered phase III clinical trials for prostate cancer in China. Meanwhile, LY01005 is currently under phase I clinical trials in the U.S. via part 505(b) (2) of the United States Federal Food, Drug and Cosmetic Act.
In February 2017, the AstraZeneca signed an agreement with the TerSera Therapeutics LLC, a specialty pharmaceutical products manufacturer for the Zoladex (goserelin acetate implant) rights across United States and Canada. Through this agreement, the AstraZeneca received payment of USD 250 million and received sales-related income through milestones totalling up to USD 70 million.


Key Target Audience
Manufacturers of Goserlein Drugs, Cancer drug manufacturers, Contract Research Organization and Governmental bodies

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Indication
  • Prostate Cancer
  • Breast Cancer
  • Endometriosis
  • Gynaecological Disorders

By Sales Channel
  • Retail Pharmacy
  • Hospital Pharmacy
  • Online Pharmacy

By Dose
  • 3.6mg
  • 10.8 mg

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Effective alternate treatment for surgery or estrogen therapy in prostate cancer
      • 3.2.2. Growing prevalence of ovarian and prostate cancer
    • 3.3. Market Challenges
      • 3.3.1. Availability of alternative drugs such as leuprorelin, triptorelin.
    • 3.4. Market Trends
      • 3.4.1. Government support to reduce cancer proliferation
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Goserelin Drug, by Indication, Sales Channel, Dose and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Goserelin Drug (Value)
      • 5.2.1. Global Goserelin Drug by: Indication (Value)
        • 5.2.1.1. Prostate Cancer
        • 5.2.1.2. Breast Cancer
        • 5.2.1.3. Endometriosis
        • 5.2.1.4. Gynaecological Disorders
      • 5.2.2. Global Goserelin Drug by: Sales Channel (Value)
        • 5.2.2.1. Retail Pharmacy
        • 5.2.2.2. Hospital Pharmacy
        • 5.2.2.3. Online Pharmacy
      • 5.2.3. Global Goserelin Drug by: Dose (Value)
        • 5.2.3.1. 3.6mg
        • 5.2.3.2. 10.8 mg
      • 5.2.4. Global Goserelin Drug Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Goserelin Drug (Volume)
      • 5.3.1. Global Goserelin Drug by: Indication (Volume)
        • 5.3.1.1. Prostate Cancer
        • 5.3.1.2. Breast Cancer
        • 5.3.1.3. Endometriosis
        • 5.3.1.4. Gynaecological Disorders
      • 5.3.2. Global Goserelin Drug by: Sales Channel (Volume)
        • 5.3.2.1. Retail Pharmacy
        • 5.3.2.2. Hospital Pharmacy
        • 5.3.2.3. Online Pharmacy
      • 5.3.3. Global Goserelin Drug by: Dose (Volume)
        • 5.3.3.1. 3.6mg
        • 5.3.3.2. 10.8 mg
      • 5.3.4. Global Goserelin Drug Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Goserelin Drug (Price)
  • 6. Goserelin Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bachem AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Aspen Holdings (South Africa)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. TerSera Therapeutics USA (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. BCN Peptides S.A (Spain)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Alvogen (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Shenzhen JYMed Technology Co., Ltd, (JYMed) (China)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Neurocrine Biosciences, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Hemmo Pharmaceuticals Pvt Ltd. (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. ALP Pharm Beijing Co., Ltd. (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Goserelin Drug Sale, by Indication, Sales Channel, Dose and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Goserelin Drug (Value)
      • 7.2.1. Global Goserelin Drug by: Indication (Value)
        • 7.2.1.1. Prostate Cancer
        • 7.2.1.2. Breast Cancer
        • 7.2.1.3. Endometriosis
        • 7.2.1.4. Gynaecological Disorders
      • 7.2.2. Global Goserelin Drug by: Sales Channel (Value)
        • 7.2.2.1. Retail Pharmacy
        • 7.2.2.2. Hospital Pharmacy
        • 7.2.2.3. Online Pharmacy
      • 7.2.3. Global Goserelin Drug by: Dose (Value)
        • 7.2.3.1. 3.6mg
        • 7.2.3.2. 10.8 mg
      • 7.2.4. Global Goserelin Drug Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Goserelin Drug (Volume)
      • 7.3.1. Global Goserelin Drug by: Indication (Volume)
        • 7.3.1.1. Prostate Cancer
        • 7.3.1.2. Breast Cancer
        • 7.3.1.3. Endometriosis
        • 7.3.1.4. Gynaecological Disorders
      • 7.3.2. Global Goserelin Drug by: Sales Channel (Volume)
        • 7.3.2.1. Retail Pharmacy
        • 7.3.2.2. Hospital Pharmacy
        • 7.3.2.3. Online Pharmacy
      • 7.3.3. Global Goserelin Drug by: Dose (Volume)
        • 7.3.3.1. 3.6mg
        • 7.3.3.2. 10.8 mg
      • 7.3.4. Global Goserelin Drug Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Goserelin Drug (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Goserelin Drug: by Indication(USD Million)
  • Table 2. Goserelin Drug Prostate Cancer , by Region USD Million (2018-2023)
  • Table 3. Goserelin Drug Breast Cancer , by Region USD Million (2018-2023)
  • Table 4. Goserelin Drug Endometriosis , by Region USD Million (2018-2023)
  • Table 5. Goserelin Drug Gynaecological Disorders , by Region USD Million (2018-2023)
  • Table 6. Goserelin Drug: by Sales Channel(USD Million)
  • Table 7. Goserelin Drug Retail Pharmacy , by Region USD Million (2018-2023)
  • Table 8. Goserelin Drug Hospital Pharmacy , by Region USD Million (2018-2023)
  • Table 9. Goserelin Drug Online Pharmacy , by Region USD Million (2018-2023)
  • Table 10. Goserelin Drug: by Dose(USD Million)
  • Table 11. Goserelin Drug 3.6mg , by Region USD Million (2018-2023)
  • Table 12. Goserelin Drug 10.8 mg , by Region USD Million (2018-2023)
  • Table 13. South America Goserelin Drug, by Country USD Million (2018-2023)
  • Table 14. South America Goserelin Drug, by Indication USD Million (2018-2023)
  • Table 15. South America Goserelin Drug, by Sales Channel USD Million (2018-2023)
  • Table 16. South America Goserelin Drug, by Dose USD Million (2018-2023)
  • Table 17. Brazil Goserelin Drug, by Indication USD Million (2018-2023)
  • Table 18. Brazil Goserelin Drug, by Sales Channel USD Million (2018-2023)
  • Table 19. Brazil Goserelin Drug, by Dose USD Million (2018-2023)
  • Table 20. Argentina Goserelin Drug, by Indication USD Million (2018-2023)
  • Table 21. Argentina Goserelin Drug, by Sales Channel USD Million (2018-2023)
  • Table 22. Argentina Goserelin Drug, by Dose USD Million (2018-2023)
  • Table 23. Rest of South America Goserelin Drug, by Indication USD Million (2018-2023)
  • Table 24. Rest of South America Goserelin Drug, by Sales Channel USD Million (2018-2023)
  • Table 25. Rest of South America Goserelin Drug, by Dose USD Million (2018-2023)
  • Table 26. Asia Pacific Goserelin Drug, by Country USD Million (2018-2023)
  • Table 27. Asia Pacific Goserelin Drug, by Indication USD Million (2018-2023)
  • Table 28. Asia Pacific Goserelin Drug, by Sales Channel USD Million (2018-2023)
  • Table 29. Asia Pacific Goserelin Drug, by Dose USD Million (2018-2023)
  • Table 30. China Goserelin Drug, by Indication USD Million (2018-2023)
  • Table 31. China Goserelin Drug, by Sales Channel USD Million (2018-2023)
  • Table 32. China Goserelin Drug, by Dose USD Million (2018-2023)
  • Table 33. Japan Goserelin Drug, by Indication USD Million (2018-2023)
  • Table 34. Japan Goserelin Drug, by Sales Channel USD Million (2018-2023)
  • Table 35. Japan Goserelin Drug, by Dose USD Million (2018-2023)
  • Table 36. India Goserelin Drug, by Indication USD Million (2018-2023)
  • Table 37. India Goserelin Drug, by Sales Channel USD Million (2018-2023)
  • Table 38. India Goserelin Drug, by Dose USD Million (2018-2023)
  • Table 39. South Korea Goserelin Drug, by Indication USD Million (2018-2023)
  • Table 40. South Korea Goserelin Drug, by Sales Channel USD Million (2018-2023)
  • Table 41. South Korea Goserelin Drug, by Dose USD Million (2018-2023)
  • Table 42. Taiwan Goserelin Drug, by Indication USD Million (2018-2023)
  • Table 43. Taiwan Goserelin Drug, by Sales Channel USD Million (2018-2023)
  • Table 44. Taiwan Goserelin Drug, by Dose USD Million (2018-2023)
  • Table 45. Australia Goserelin Drug, by Indication USD Million (2018-2023)
  • Table 46. Australia Goserelin Drug, by Sales Channel USD Million (2018-2023)
  • Table 47. Australia Goserelin Drug, by Dose USD Million (2018-2023)
  • Table 48. Rest of Asia-Pacific Goserelin Drug, by Indication USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Goserelin Drug, by Sales Channel USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Goserelin Drug, by Dose USD Million (2018-2023)
  • Table 51. Europe Goserelin Drug, by Country USD Million (2018-2023)
  • Table 52. Europe Goserelin Drug, by Indication USD Million (2018-2023)
  • Table 53. Europe Goserelin Drug, by Sales Channel USD Million (2018-2023)
  • Table 54. Europe Goserelin Drug, by Dose USD Million (2018-2023)
  • Table 55. Germany Goserelin Drug, by Indication USD Million (2018-2023)
  • Table 56. Germany Goserelin Drug, by Sales Channel USD Million (2018-2023)
  • Table 57. Germany Goserelin Drug, by Dose USD Million (2018-2023)
  • Table 58. France Goserelin Drug, by Indication USD Million (2018-2023)
  • Table 59. France Goserelin Drug, by Sales Channel USD Million (2018-2023)
  • Table 60. France Goserelin Drug, by Dose USD Million (2018-2023)
  • Table 61. Italy Goserelin Drug, by Indication USD Million (2018-2023)
  • Table 62. Italy Goserelin Drug, by Sales Channel USD Million (2018-2023)
  • Table 63. Italy Goserelin Drug, by Dose USD Million (2018-2023)
  • Table 64. United Kingdom Goserelin Drug, by Indication USD Million (2018-2023)
  • Table 65. United Kingdom Goserelin Drug, by Sales Channel USD Million (2018-2023)
  • Table 66. United Kingdom Goserelin Drug, by Dose USD Million (2018-2023)
  • Table 67. Netherlands Goserelin Drug, by Indication USD Million (2018-2023)
  • Table 68. Netherlands Goserelin Drug, by Sales Channel USD Million (2018-2023)
  • Table 69. Netherlands Goserelin Drug, by Dose USD Million (2018-2023)
  • Table 70. Rest of Europe Goserelin Drug, by Indication USD Million (2018-2023)
  • Table 71. Rest of Europe Goserelin Drug, by Sales Channel USD Million (2018-2023)
  • Table 72. Rest of Europe Goserelin Drug, by Dose USD Million (2018-2023)
  • Table 73. MEA Goserelin Drug, by Country USD Million (2018-2023)
  • Table 74. MEA Goserelin Drug, by Indication USD Million (2018-2023)
  • Table 75. MEA Goserelin Drug, by Sales Channel USD Million (2018-2023)
  • Table 76. MEA Goserelin Drug, by Dose USD Million (2018-2023)
  • Table 77. Middle East Goserelin Drug, by Indication USD Million (2018-2023)
  • Table 78. Middle East Goserelin Drug, by Sales Channel USD Million (2018-2023)
  • Table 79. Middle East Goserelin Drug, by Dose USD Million (2018-2023)
  • Table 80. Africa Goserelin Drug, by Indication USD Million (2018-2023)
  • Table 81. Africa Goserelin Drug, by Sales Channel USD Million (2018-2023)
  • Table 82. Africa Goserelin Drug, by Dose USD Million (2018-2023)
  • Table 83. North America Goserelin Drug, by Country USD Million (2018-2023)
  • Table 84. North America Goserelin Drug, by Indication USD Million (2018-2023)
  • Table 85. North America Goserelin Drug, by Sales Channel USD Million (2018-2023)
  • Table 86. North America Goserelin Drug, by Dose USD Million (2018-2023)
  • Table 87. United States Goserelin Drug, by Indication USD Million (2018-2023)
  • Table 88. United States Goserelin Drug, by Sales Channel USD Million (2018-2023)
  • Table 89. United States Goserelin Drug, by Dose USD Million (2018-2023)
  • Table 90. Canada Goserelin Drug, by Indication USD Million (2018-2023)
  • Table 91. Canada Goserelin Drug, by Sales Channel USD Million (2018-2023)
  • Table 92. Canada Goserelin Drug, by Dose USD Million (2018-2023)
  • Table 93. Mexico Goserelin Drug, by Indication USD Million (2018-2023)
  • Table 94. Mexico Goserelin Drug, by Sales Channel USD Million (2018-2023)
  • Table 95. Mexico Goserelin Drug, by Dose USD Million (2018-2023)
  • Table 96. Goserelin Drug Sales: by Indication(K Tone)
  • Table 97. Goserelin Drug Sales Prostate Cancer , by Region K Tone (2018-2023)
  • Table 98. Goserelin Drug Sales Breast Cancer , by Region K Tone (2018-2023)
  • Table 99. Goserelin Drug Sales Endometriosis , by Region K Tone (2018-2023)
  • Table 100. Goserelin Drug Sales Gynaecological Disorders , by Region K Tone (2018-2023)
  • Table 101. Goserelin Drug Sales: by Sales Channel(K Tone)
  • Table 102. Goserelin Drug Sales Retail Pharmacy , by Region K Tone (2018-2023)
  • Table 103. Goserelin Drug Sales Hospital Pharmacy , by Region K Tone (2018-2023)
  • Table 104. Goserelin Drug Sales Online Pharmacy , by Region K Tone (2018-2023)
  • Table 105. Goserelin Drug Sales: by Dose(K Tone)
  • Table 106. Goserelin Drug Sales 3.6mg , by Region K Tone (2018-2023)
  • Table 107. Goserelin Drug Sales 10.8 mg , by Region K Tone (2018-2023)
  • Table 108. South America Goserelin Drug Sales, by Country K Tone (2018-2023)
  • Table 109. South America Goserelin Drug Sales, by Indication K Tone (2018-2023)
  • Table 110. South America Goserelin Drug Sales, by Sales Channel K Tone (2018-2023)
  • Table 111. South America Goserelin Drug Sales, by Dose K Tone (2018-2023)
  • Table 112. Brazil Goserelin Drug Sales, by Indication K Tone (2018-2023)
  • Table 113. Brazil Goserelin Drug Sales, by Sales Channel K Tone (2018-2023)
  • Table 114. Brazil Goserelin Drug Sales, by Dose K Tone (2018-2023)
  • Table 115. Argentina Goserelin Drug Sales, by Indication K Tone (2018-2023)
  • Table 116. Argentina Goserelin Drug Sales, by Sales Channel K Tone (2018-2023)
  • Table 117. Argentina Goserelin Drug Sales, by Dose K Tone (2018-2023)
  • Table 118. Rest of South America Goserelin Drug Sales, by Indication K Tone (2018-2023)
  • Table 119. Rest of South America Goserelin Drug Sales, by Sales Channel K Tone (2018-2023)
  • Table 120. Rest of South America Goserelin Drug Sales, by Dose K Tone (2018-2023)
  • Table 121. Asia Pacific Goserelin Drug Sales, by Country K Tone (2018-2023)
  • Table 122. Asia Pacific Goserelin Drug Sales, by Indication K Tone (2018-2023)
  • Table 123. Asia Pacific Goserelin Drug Sales, by Sales Channel K Tone (2018-2023)
  • Table 124. Asia Pacific Goserelin Drug Sales, by Dose K Tone (2018-2023)
  • Table 125. China Goserelin Drug Sales, by Indication K Tone (2018-2023)
  • Table 126. China Goserelin Drug Sales, by Sales Channel K Tone (2018-2023)
  • Table 127. China Goserelin Drug Sales, by Dose K Tone (2018-2023)
  • Table 128. Japan Goserelin Drug Sales, by Indication K Tone (2018-2023)
  • Table 129. Japan Goserelin Drug Sales, by Sales Channel K Tone (2018-2023)
  • Table 130. Japan Goserelin Drug Sales, by Dose K Tone (2018-2023)
  • Table 131. India Goserelin Drug Sales, by Indication K Tone (2018-2023)
  • Table 132. India Goserelin Drug Sales, by Sales Channel K Tone (2018-2023)
  • Table 133. India Goserelin Drug Sales, by Dose K Tone (2018-2023)
  • Table 134. South Korea Goserelin Drug Sales, by Indication K Tone (2018-2023)
  • Table 135. South Korea Goserelin Drug Sales, by Sales Channel K Tone (2018-2023)
  • Table 136. South Korea Goserelin Drug Sales, by Dose K Tone (2018-2023)
  • Table 137. Taiwan Goserelin Drug Sales, by Indication K Tone (2018-2023)
  • Table 138. Taiwan Goserelin Drug Sales, by Sales Channel K Tone (2018-2023)
  • Table 139. Taiwan Goserelin Drug Sales, by Dose K Tone (2018-2023)
  • Table 140. Australia Goserelin Drug Sales, by Indication K Tone (2018-2023)
  • Table 141. Australia Goserelin Drug Sales, by Sales Channel K Tone (2018-2023)
  • Table 142. Australia Goserelin Drug Sales, by Dose K Tone (2018-2023)
  • Table 143. Rest of Asia-Pacific Goserelin Drug Sales, by Indication K Tone (2018-2023)
  • Table 144. Rest of Asia-Pacific Goserelin Drug Sales, by Sales Channel K Tone (2018-2023)
  • Table 145. Rest of Asia-Pacific Goserelin Drug Sales, by Dose K Tone (2018-2023)
  • Table 146. Europe Goserelin Drug Sales, by Country K Tone (2018-2023)
  • Table 147. Europe Goserelin Drug Sales, by Indication K Tone (2018-2023)
  • Table 148. Europe Goserelin Drug Sales, by Sales Channel K Tone (2018-2023)
  • Table 149. Europe Goserelin Drug Sales, by Dose K Tone (2018-2023)
  • Table 150. Germany Goserelin Drug Sales, by Indication K Tone (2018-2023)
  • Table 151. Germany Goserelin Drug Sales, by Sales Channel K Tone (2018-2023)
  • Table 152. Germany Goserelin Drug Sales, by Dose K Tone (2018-2023)
  • Table 153. France Goserelin Drug Sales, by Indication K Tone (2018-2023)
  • Table 154. France Goserelin Drug Sales, by Sales Channel K Tone (2018-2023)
  • Table 155. France Goserelin Drug Sales, by Dose K Tone (2018-2023)
  • Table 156. Italy Goserelin Drug Sales, by Indication K Tone (2018-2023)
  • Table 157. Italy Goserelin Drug Sales, by Sales Channel K Tone (2018-2023)
  • Table 158. Italy Goserelin Drug Sales, by Dose K Tone (2018-2023)
  • Table 159. United Kingdom Goserelin Drug Sales, by Indication K Tone (2018-2023)
  • Table 160. United Kingdom Goserelin Drug Sales, by Sales Channel K Tone (2018-2023)
  • Table 161. United Kingdom Goserelin Drug Sales, by Dose K Tone (2018-2023)
  • Table 162. Netherlands Goserelin Drug Sales, by Indication K Tone (2018-2023)
  • Table 163. Netherlands Goserelin Drug Sales, by Sales Channel K Tone (2018-2023)
  • Table 164. Netherlands Goserelin Drug Sales, by Dose K Tone (2018-2023)
  • Table 165. Rest of Europe Goserelin Drug Sales, by Indication K Tone (2018-2023)
  • Table 166. Rest of Europe Goserelin Drug Sales, by Sales Channel K Tone (2018-2023)
  • Table 167. Rest of Europe Goserelin Drug Sales, by Dose K Tone (2018-2023)
  • Table 168. MEA Goserelin Drug Sales, by Country K Tone (2018-2023)
  • Table 169. MEA Goserelin Drug Sales, by Indication K Tone (2018-2023)
  • Table 170. MEA Goserelin Drug Sales, by Sales Channel K Tone (2018-2023)
  • Table 171. MEA Goserelin Drug Sales, by Dose K Tone (2018-2023)
  • Table 172. Middle East Goserelin Drug Sales, by Indication K Tone (2018-2023)
  • Table 173. Middle East Goserelin Drug Sales, by Sales Channel K Tone (2018-2023)
  • Table 174. Middle East Goserelin Drug Sales, by Dose K Tone (2018-2023)
  • Table 175. Africa Goserelin Drug Sales, by Indication K Tone (2018-2023)
  • Table 176. Africa Goserelin Drug Sales, by Sales Channel K Tone (2018-2023)
  • Table 177. Africa Goserelin Drug Sales, by Dose K Tone (2018-2023)
  • Table 178. North America Goserelin Drug Sales, by Country K Tone (2018-2023)
  • Table 179. North America Goserelin Drug Sales, by Indication K Tone (2018-2023)
  • Table 180. North America Goserelin Drug Sales, by Sales Channel K Tone (2018-2023)
  • Table 181. North America Goserelin Drug Sales, by Dose K Tone (2018-2023)
  • Table 182. United States Goserelin Drug Sales, by Indication K Tone (2018-2023)
  • Table 183. United States Goserelin Drug Sales, by Sales Channel K Tone (2018-2023)
  • Table 184. United States Goserelin Drug Sales, by Dose K Tone (2018-2023)
  • Table 185. Canada Goserelin Drug Sales, by Indication K Tone (2018-2023)
  • Table 186. Canada Goserelin Drug Sales, by Sales Channel K Tone (2018-2023)
  • Table 187. Canada Goserelin Drug Sales, by Dose K Tone (2018-2023)
  • Table 188. Mexico Goserelin Drug Sales, by Indication K Tone (2018-2023)
  • Table 189. Mexico Goserelin Drug Sales, by Sales Channel K Tone (2018-2023)
  • Table 190. Mexico Goserelin Drug Sales, by Dose K Tone (2018-2023)
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Goserelin Drug: by Indication(USD Million)
  • Table 201. Goserelin Drug Prostate Cancer , by Region USD Million (2025-2030)
  • Table 202. Goserelin Drug Breast Cancer , by Region USD Million (2025-2030)
  • Table 203. Goserelin Drug Endometriosis , by Region USD Million (2025-2030)
  • Table 204. Goserelin Drug Gynaecological Disorders , by Region USD Million (2025-2030)
  • Table 205. Goserelin Drug: by Sales Channel(USD Million)
  • Table 206. Goserelin Drug Retail Pharmacy , by Region USD Million (2025-2030)
  • Table 207. Goserelin Drug Hospital Pharmacy , by Region USD Million (2025-2030)
  • Table 208. Goserelin Drug Online Pharmacy , by Region USD Million (2025-2030)
  • Table 209. Goserelin Drug: by Dose(USD Million)
  • Table 210. Goserelin Drug 3.6mg , by Region USD Million (2025-2030)
  • Table 211. Goserelin Drug 10.8 mg , by Region USD Million (2025-2030)
  • Table 212. South America Goserelin Drug, by Country USD Million (2025-2030)
  • Table 213. South America Goserelin Drug, by Indication USD Million (2025-2030)
  • Table 214. South America Goserelin Drug, by Sales Channel USD Million (2025-2030)
  • Table 215. South America Goserelin Drug, by Dose USD Million (2025-2030)
  • Table 216. Brazil Goserelin Drug, by Indication USD Million (2025-2030)
  • Table 217. Brazil Goserelin Drug, by Sales Channel USD Million (2025-2030)
  • Table 218. Brazil Goserelin Drug, by Dose USD Million (2025-2030)
  • Table 219. Argentina Goserelin Drug, by Indication USD Million (2025-2030)
  • Table 220. Argentina Goserelin Drug, by Sales Channel USD Million (2025-2030)
  • Table 221. Argentina Goserelin Drug, by Dose USD Million (2025-2030)
  • Table 222. Rest of South America Goserelin Drug, by Indication USD Million (2025-2030)
  • Table 223. Rest of South America Goserelin Drug, by Sales Channel USD Million (2025-2030)
  • Table 224. Rest of South America Goserelin Drug, by Dose USD Million (2025-2030)
  • Table 225. Asia Pacific Goserelin Drug, by Country USD Million (2025-2030)
  • Table 226. Asia Pacific Goserelin Drug, by Indication USD Million (2025-2030)
  • Table 227. Asia Pacific Goserelin Drug, by Sales Channel USD Million (2025-2030)
  • Table 228. Asia Pacific Goserelin Drug, by Dose USD Million (2025-2030)
  • Table 229. China Goserelin Drug, by Indication USD Million (2025-2030)
  • Table 230. China Goserelin Drug, by Sales Channel USD Million (2025-2030)
  • Table 231. China Goserelin Drug, by Dose USD Million (2025-2030)
  • Table 232. Japan Goserelin Drug, by Indication USD Million (2025-2030)
  • Table 233. Japan Goserelin Drug, by Sales Channel USD Million (2025-2030)
  • Table 234. Japan Goserelin Drug, by Dose USD Million (2025-2030)
  • Table 235. India Goserelin Drug, by Indication USD Million (2025-2030)
  • Table 236. India Goserelin Drug, by Sales Channel USD Million (2025-2030)
  • Table 237. India Goserelin Drug, by Dose USD Million (2025-2030)
  • Table 238. South Korea Goserelin Drug, by Indication USD Million (2025-2030)
  • Table 239. South Korea Goserelin Drug, by Sales Channel USD Million (2025-2030)
  • Table 240. South Korea Goserelin Drug, by Dose USD Million (2025-2030)
  • Table 241. Taiwan Goserelin Drug, by Indication USD Million (2025-2030)
  • Table 242. Taiwan Goserelin Drug, by Sales Channel USD Million (2025-2030)
  • Table 243. Taiwan Goserelin Drug, by Dose USD Million (2025-2030)
  • Table 244. Australia Goserelin Drug, by Indication USD Million (2025-2030)
  • Table 245. Australia Goserelin Drug, by Sales Channel USD Million (2025-2030)
  • Table 246. Australia Goserelin Drug, by Dose USD Million (2025-2030)
  • Table 247. Rest of Asia-Pacific Goserelin Drug, by Indication USD Million (2025-2030)
  • Table 248. Rest of Asia-Pacific Goserelin Drug, by Sales Channel USD Million (2025-2030)
  • Table 249. Rest of Asia-Pacific Goserelin Drug, by Dose USD Million (2025-2030)
  • Table 250. Europe Goserelin Drug, by Country USD Million (2025-2030)
  • Table 251. Europe Goserelin Drug, by Indication USD Million (2025-2030)
  • Table 252. Europe Goserelin Drug, by Sales Channel USD Million (2025-2030)
  • Table 253. Europe Goserelin Drug, by Dose USD Million (2025-2030)
  • Table 254. Germany Goserelin Drug, by Indication USD Million (2025-2030)
  • Table 255. Germany Goserelin Drug, by Sales Channel USD Million (2025-2030)
  • Table 256. Germany Goserelin Drug, by Dose USD Million (2025-2030)
  • Table 257. France Goserelin Drug, by Indication USD Million (2025-2030)
  • Table 258. France Goserelin Drug, by Sales Channel USD Million (2025-2030)
  • Table 259. France Goserelin Drug, by Dose USD Million (2025-2030)
  • Table 260. Italy Goserelin Drug, by Indication USD Million (2025-2030)
  • Table 261. Italy Goserelin Drug, by Sales Channel USD Million (2025-2030)
  • Table 262. Italy Goserelin Drug, by Dose USD Million (2025-2030)
  • Table 263. United Kingdom Goserelin Drug, by Indication USD Million (2025-2030)
  • Table 264. United Kingdom Goserelin Drug, by Sales Channel USD Million (2025-2030)
  • Table 265. United Kingdom Goserelin Drug, by Dose USD Million (2025-2030)
  • Table 266. Netherlands Goserelin Drug, by Indication USD Million (2025-2030)
  • Table 267. Netherlands Goserelin Drug, by Sales Channel USD Million (2025-2030)
  • Table 268. Netherlands Goserelin Drug, by Dose USD Million (2025-2030)
  • Table 269. Rest of Europe Goserelin Drug, by Indication USD Million (2025-2030)
  • Table 270. Rest of Europe Goserelin Drug, by Sales Channel USD Million (2025-2030)
  • Table 271. Rest of Europe Goserelin Drug, by Dose USD Million (2025-2030)
  • Table 272. MEA Goserelin Drug, by Country USD Million (2025-2030)
  • Table 273. MEA Goserelin Drug, by Indication USD Million (2025-2030)
  • Table 274. MEA Goserelin Drug, by Sales Channel USD Million (2025-2030)
  • Table 275. MEA Goserelin Drug, by Dose USD Million (2025-2030)
  • Table 276. Middle East Goserelin Drug, by Indication USD Million (2025-2030)
  • Table 277. Middle East Goserelin Drug, by Sales Channel USD Million (2025-2030)
  • Table 278. Middle East Goserelin Drug, by Dose USD Million (2025-2030)
  • Table 279. Africa Goserelin Drug, by Indication USD Million (2025-2030)
  • Table 280. Africa Goserelin Drug, by Sales Channel USD Million (2025-2030)
  • Table 281. Africa Goserelin Drug, by Dose USD Million (2025-2030)
  • Table 282. North America Goserelin Drug, by Country USD Million (2025-2030)
  • Table 283. North America Goserelin Drug, by Indication USD Million (2025-2030)
  • Table 284. North America Goserelin Drug, by Sales Channel USD Million (2025-2030)
  • Table 285. North America Goserelin Drug, by Dose USD Million (2025-2030)
  • Table 286. United States Goserelin Drug, by Indication USD Million (2025-2030)
  • Table 287. United States Goserelin Drug, by Sales Channel USD Million (2025-2030)
  • Table 288. United States Goserelin Drug, by Dose USD Million (2025-2030)
  • Table 289. Canada Goserelin Drug, by Indication USD Million (2025-2030)
  • Table 290. Canada Goserelin Drug, by Sales Channel USD Million (2025-2030)
  • Table 291. Canada Goserelin Drug, by Dose USD Million (2025-2030)
  • Table 292. Mexico Goserelin Drug, by Indication USD Million (2025-2030)
  • Table 293. Mexico Goserelin Drug, by Sales Channel USD Million (2025-2030)
  • Table 294. Mexico Goserelin Drug, by Dose USD Million (2025-2030)
  • Table 295. Goserelin Drug Sales: by Indication(K Tone)
  • Table 296. Goserelin Drug Sales Prostate Cancer , by Region K Tone (2025-2030)
  • Table 297. Goserelin Drug Sales Breast Cancer , by Region K Tone (2025-2030)
  • Table 298. Goserelin Drug Sales Endometriosis , by Region K Tone (2025-2030)
  • Table 299. Goserelin Drug Sales Gynaecological Disorders , by Region K Tone (2025-2030)
  • Table 300. Goserelin Drug Sales: by Sales Channel(K Tone)
  • Table 301. Goserelin Drug Sales Retail Pharmacy , by Region K Tone (2025-2030)
  • Table 302. Goserelin Drug Sales Hospital Pharmacy , by Region K Tone (2025-2030)
  • Table 303. Goserelin Drug Sales Online Pharmacy , by Region K Tone (2025-2030)
  • Table 304. Goserelin Drug Sales: by Dose(K Tone)
  • Table 305. Goserelin Drug Sales 3.6mg , by Region K Tone (2025-2030)
  • Table 306. Goserelin Drug Sales 10.8 mg , by Region K Tone (2025-2030)
  • Table 307. South America Goserelin Drug Sales, by Country K Tone (2025-2030)
  • Table 308. South America Goserelin Drug Sales, by Indication K Tone (2025-2030)
  • Table 309. South America Goserelin Drug Sales, by Sales Channel K Tone (2025-2030)
  • Table 310. South America Goserelin Drug Sales, by Dose K Tone (2025-2030)
  • Table 311. Brazil Goserelin Drug Sales, by Indication K Tone (2025-2030)
  • Table 312. Brazil Goserelin Drug Sales, by Sales Channel K Tone (2025-2030)
  • Table 313. Brazil Goserelin Drug Sales, by Dose K Tone (2025-2030)
  • Table 314. Argentina Goserelin Drug Sales, by Indication K Tone (2025-2030)
  • Table 315. Argentina Goserelin Drug Sales, by Sales Channel K Tone (2025-2030)
  • Table 316. Argentina Goserelin Drug Sales, by Dose K Tone (2025-2030)
  • Table 317. Rest of South America Goserelin Drug Sales, by Indication K Tone (2025-2030)
  • Table 318. Rest of South America Goserelin Drug Sales, by Sales Channel K Tone (2025-2030)
  • Table 319. Rest of South America Goserelin Drug Sales, by Dose K Tone (2025-2030)
  • Table 320. Asia Pacific Goserelin Drug Sales, by Country K Tone (2025-2030)
  • Table 321. Asia Pacific Goserelin Drug Sales, by Indication K Tone (2025-2030)
  • Table 322. Asia Pacific Goserelin Drug Sales, by Sales Channel K Tone (2025-2030)
  • Table 323. Asia Pacific Goserelin Drug Sales, by Dose K Tone (2025-2030)
  • Table 324. China Goserelin Drug Sales, by Indication K Tone (2025-2030)
  • Table 325. China Goserelin Drug Sales, by Sales Channel K Tone (2025-2030)
  • Table 326. China Goserelin Drug Sales, by Dose K Tone (2025-2030)
  • Table 327. Japan Goserelin Drug Sales, by Indication K Tone (2025-2030)
  • Table 328. Japan Goserelin Drug Sales, by Sales Channel K Tone (2025-2030)
  • Table 329. Japan Goserelin Drug Sales, by Dose K Tone (2025-2030)
  • Table 330. India Goserelin Drug Sales, by Indication K Tone (2025-2030)
  • Table 331. India Goserelin Drug Sales, by Sales Channel K Tone (2025-2030)
  • Table 332. India Goserelin Drug Sales, by Dose K Tone (2025-2030)
  • Table 333. South Korea Goserelin Drug Sales, by Indication K Tone (2025-2030)
  • Table 334. South Korea Goserelin Drug Sales, by Sales Channel K Tone (2025-2030)
  • Table 335. South Korea Goserelin Drug Sales, by Dose K Tone (2025-2030)
  • Table 336. Taiwan Goserelin Drug Sales, by Indication K Tone (2025-2030)
  • Table 337. Taiwan Goserelin Drug Sales, by Sales Channel K Tone (2025-2030)
  • Table 338. Taiwan Goserelin Drug Sales, by Dose K Tone (2025-2030)
  • Table 339. Australia Goserelin Drug Sales, by Indication K Tone (2025-2030)
  • Table 340. Australia Goserelin Drug Sales, by Sales Channel K Tone (2025-2030)
  • Table 341. Australia Goserelin Drug Sales, by Dose K Tone (2025-2030)
  • Table 342. Rest of Asia-Pacific Goserelin Drug Sales, by Indication K Tone (2025-2030)
  • Table 343. Rest of Asia-Pacific Goserelin Drug Sales, by Sales Channel K Tone (2025-2030)
  • Table 344. Rest of Asia-Pacific Goserelin Drug Sales, by Dose K Tone (2025-2030)
  • Table 345. Europe Goserelin Drug Sales, by Country K Tone (2025-2030)
  • Table 346. Europe Goserelin Drug Sales, by Indication K Tone (2025-2030)
  • Table 347. Europe Goserelin Drug Sales, by Sales Channel K Tone (2025-2030)
  • Table 348. Europe Goserelin Drug Sales, by Dose K Tone (2025-2030)
  • Table 349. Germany Goserelin Drug Sales, by Indication K Tone (2025-2030)
  • Table 350. Germany Goserelin Drug Sales, by Sales Channel K Tone (2025-2030)
  • Table 351. Germany Goserelin Drug Sales, by Dose K Tone (2025-2030)
  • Table 352. France Goserelin Drug Sales, by Indication K Tone (2025-2030)
  • Table 353. France Goserelin Drug Sales, by Sales Channel K Tone (2025-2030)
  • Table 354. France Goserelin Drug Sales, by Dose K Tone (2025-2030)
  • Table 355. Italy Goserelin Drug Sales, by Indication K Tone (2025-2030)
  • Table 356. Italy Goserelin Drug Sales, by Sales Channel K Tone (2025-2030)
  • Table 357. Italy Goserelin Drug Sales, by Dose K Tone (2025-2030)
  • Table 358. United Kingdom Goserelin Drug Sales, by Indication K Tone (2025-2030)
  • Table 359. United Kingdom Goserelin Drug Sales, by Sales Channel K Tone (2025-2030)
  • Table 360. United Kingdom Goserelin Drug Sales, by Dose K Tone (2025-2030)
  • Table 361. Netherlands Goserelin Drug Sales, by Indication K Tone (2025-2030)
  • Table 362. Netherlands Goserelin Drug Sales, by Sales Channel K Tone (2025-2030)
  • Table 363. Netherlands Goserelin Drug Sales, by Dose K Tone (2025-2030)
  • Table 364. Rest of Europe Goserelin Drug Sales, by Indication K Tone (2025-2030)
  • Table 365. Rest of Europe Goserelin Drug Sales, by Sales Channel K Tone (2025-2030)
  • Table 366. Rest of Europe Goserelin Drug Sales, by Dose K Tone (2025-2030)
  • Table 367. MEA Goserelin Drug Sales, by Country K Tone (2025-2030)
  • Table 368. MEA Goserelin Drug Sales, by Indication K Tone (2025-2030)
  • Table 369. MEA Goserelin Drug Sales, by Sales Channel K Tone (2025-2030)
  • Table 370. MEA Goserelin Drug Sales, by Dose K Tone (2025-2030)
  • Table 371. Middle East Goserelin Drug Sales, by Indication K Tone (2025-2030)
  • Table 372. Middle East Goserelin Drug Sales, by Sales Channel K Tone (2025-2030)
  • Table 373. Middle East Goserelin Drug Sales, by Dose K Tone (2025-2030)
  • Table 374. Africa Goserelin Drug Sales, by Indication K Tone (2025-2030)
  • Table 375. Africa Goserelin Drug Sales, by Sales Channel K Tone (2025-2030)
  • Table 376. Africa Goserelin Drug Sales, by Dose K Tone (2025-2030)
  • Table 377. North America Goserelin Drug Sales, by Country K Tone (2025-2030)
  • Table 378. North America Goserelin Drug Sales, by Indication K Tone (2025-2030)
  • Table 379. North America Goserelin Drug Sales, by Sales Channel K Tone (2025-2030)
  • Table 380. North America Goserelin Drug Sales, by Dose K Tone (2025-2030)
  • Table 381. United States Goserelin Drug Sales, by Indication K Tone (2025-2030)
  • Table 382. United States Goserelin Drug Sales, by Sales Channel K Tone (2025-2030)
  • Table 383. United States Goserelin Drug Sales, by Dose K Tone (2025-2030)
  • Table 384. Canada Goserelin Drug Sales, by Indication K Tone (2025-2030)
  • Table 385. Canada Goserelin Drug Sales, by Sales Channel K Tone (2025-2030)
  • Table 386. Canada Goserelin Drug Sales, by Dose K Tone (2025-2030)
  • Table 387. Mexico Goserelin Drug Sales, by Indication K Tone (2025-2030)
  • Table 388. Mexico Goserelin Drug Sales, by Sales Channel K Tone (2025-2030)
  • Table 389. Mexico Goserelin Drug Sales, by Dose K Tone (2025-2030)
  • Table 390. Research Programs/Design for This Report
  • Table 391. Key Data Information from Secondary Sources
  • Table 392. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Goserelin Drug: by Indication USD Million (2018-2023)
  • Figure 5. Global Goserelin Drug: by Sales Channel USD Million (2018-2023)
  • Figure 6. Global Goserelin Drug: by Dose USD Million (2018-2023)
  • Figure 7. South America Goserelin Drug Share (%), by Country
  • Figure 8. Asia Pacific Goserelin Drug Share (%), by Country
  • Figure 9. Europe Goserelin Drug Share (%), by Country
  • Figure 10. MEA Goserelin Drug Share (%), by Country
  • Figure 11. North America Goserelin Drug Share (%), by Country
  • Figure 12. Global Goserelin Drug: by Indication K Tone (2018-2023)
  • Figure 13. Global Goserelin Drug: by Sales Channel K Tone (2018-2023)
  • Figure 14. Global Goserelin Drug: by Dose K Tone (2018-2023)
  • Figure 15. South America Goserelin Drug Share (%), by Country
  • Figure 16. Asia Pacific Goserelin Drug Share (%), by Country
  • Figure 17. Europe Goserelin Drug Share (%), by Country
  • Figure 18. MEA Goserelin Drug Share (%), by Country
  • Figure 19. North America Goserelin Drug Share (%), by Country
  • Figure 20. Global Goserelin Drug share by Players 2023 (%)
  • Figure 21. Global Goserelin Drug share by Players (Top 3) 2023(%)
  • Figure 22. Global Goserelin Drug share by Players (Top 5) 2023(%)
  • Figure 23. BCG Matrix for key Companies
  • Figure 24. Bachem AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Bachem AG (Switzerland) Revenue: by Geography 2023
  • Figure 26. Aspen Holdings (South Africa) Revenue, Net Income and Gross profit
  • Figure 27. Aspen Holdings (South Africa) Revenue: by Geography 2023
  • Figure 28. TerSera Therapeutics USA (United States) Revenue, Net Income and Gross profit
  • Figure 29. TerSera Therapeutics USA (United States) Revenue: by Geography 2023
  • Figure 30. BCN Peptides S.A (Spain) Revenue, Net Income and Gross profit
  • Figure 31. BCN Peptides S.A (Spain) Revenue: by Geography 2023
  • Figure 32. Alvogen (United States) Revenue, Net Income and Gross profit
  • Figure 33. Alvogen (United States) Revenue: by Geography 2023
  • Figure 34. Shenzhen JYMed Technology Co., Ltd, (JYMed) (China) Revenue, Net Income and Gross profit
  • Figure 35. Shenzhen JYMed Technology Co., Ltd, (JYMed) (China) Revenue: by Geography 2023
  • Figure 36. Neurocrine Biosciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Neurocrine Biosciences, Inc. (United States) Revenue: by Geography 2023
  • Figure 38. Hemmo Pharmaceuticals Pvt Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 39. Hemmo Pharmaceuticals Pvt Ltd. (India) Revenue: by Geography 2023
  • Figure 40. ALP Pharm Beijing Co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 41. ALP Pharm Beijing Co., Ltd. (China) Revenue: by Geography 2023
  • Figure 42. Global Goserelin Drug: by Indication USD Million (2025-2030)
  • Figure 43. Global Goserelin Drug: by Sales Channel USD Million (2025-2030)
  • Figure 44. Global Goserelin Drug: by Dose USD Million (2025-2030)
  • Figure 45. South America Goserelin Drug Share (%), by Country
  • Figure 46. Asia Pacific Goserelin Drug Share (%), by Country
  • Figure 47. Europe Goserelin Drug Share (%), by Country
  • Figure 48. MEA Goserelin Drug Share (%), by Country
  • Figure 49. North America Goserelin Drug Share (%), by Country
  • Figure 50. Global Goserelin Drug: by Indication K Tone (2025-2030)
  • Figure 51. Global Goserelin Drug: by Sales Channel K Tone (2025-2030)
  • Figure 52. Global Goserelin Drug: by Dose K Tone (2025-2030)
  • Figure 53. South America Goserelin Drug Share (%), by Country
  • Figure 54. Asia Pacific Goserelin Drug Share (%), by Country
  • Figure 55. Europe Goserelin Drug Share (%), by Country
  • Figure 56. MEA Goserelin Drug Share (%), by Country
  • Figure 57. North America Goserelin Drug Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Bachem AG (Switzerland)
  • Aspen Holdings (South Africa)
  • TerSera Therapeutics USA (United States)
  • BCN Peptides S.A (Spain)
  • Alvogen (United States)
  • Shenzhen JYMed Technology Co., Ltd, (JYMed) (China)
  • Neurocrine Biosciences, Inc. (United States)
  • Hemmo Pharmaceuticals Pvt Ltd. (India)
  • ALP Pharm Beijing Co., Ltd. (China)
Select User Access Type

Key Highlights of Report


Mar 2024 236 Pages 62 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Goserelin Drug Market Quantitative research analysis
Global Goserelin Drug Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Bachem AG (Switzerland), Aspen Holdings (South Africa), TerSera Therapeutics USA (United States), BCN Peptides S.A (Spain), Alvogen (United States), Shenzhen JYMed Technology Co., Ltd, (JYMed) (China), Neurocrine Biosciences, Inc. (United States), Hemmo Pharmaceuticals Pvt Ltd. (India) and ALP Pharm Beijing Co., Ltd. (China) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Government support to reduce cancer proliferation" is seen as one of major influencing trends for Goserelin Drug Market during projected period 2023-2030.
The Goserelin Drug market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Goserelin Drug Market Report?

Have a Query? Click Here

Other Related Reports

Paediatric Palliative Care Drugs Comprehensive Study by Type (Paracetamol, Ibuprofen, Morphine, Others), Route of Administration (Oral, Topical, Parenteral), Distribution Channel (Hospital Pharmacies...
$ 3450
Drug Repurposing Comprehensive Study by Type (De novo drug discovery, Personalized Medicine, Genomics, Gene Editing), Application (Discovering drug targets,, Identifying and optimizing lead compounds...
$ 3650
Cyclobenzaprine Comprehensive Study by Patient Type (Adult, Pediatric), Form (Tablet, Capsule), Distribution Channel (Hospitals & Clinics, Retail Pharmacies, Online Pharmacies), Dosage (5 mg, 7.5 mg,...
$ 3350
Pharmaceutical Contract Development and Manufacturing Comprehensive Study by Application (Big Pharma, Small & Mid-size Pharma, Generic Pharmaceutical Companies, Other End Users), Services (Pharmaceut...
$ 3750
Tablet Coatings Comprehensive Study by Type (Sugar Coating, Sealing, Sub Coating, Syrup Coating, Colouring, Polishing), Application (Nutraceuticals, Pharmaceuticals), Polymers (Cellulosic, Vinyl, Acr...
$ 3500
Ganirelix Comprehensive Study by Application (Infertility, Controlled Ovarian Stimulation, IVF Treatment, Premature Ovarian Failure (POF)), Form (Injection, Solution), Packaging (Single syringe, Box ...
$ 3650